TY - JOUR
T1 - Sharing the cure
T2 - Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland
AU - Irvin, Risha
AU - Ntiri-Reid, Boatemaa
AU - Kleinman, Mary
AU - Agee, Tracy
AU - Hitt, Jeffrey
AU - Anaedozie, Onyeka
AU - Arowolo, Tolu
AU - Cassidy-Stewart, Hope
AU - Bush, Ca Saundra
AU - Wilson, Lucy E.
AU - Millman, Alexander J.
AU - Nelson, Noele P.
AU - Canary, Lauren
AU - Brinkley, Sherilyn
AU - Moon, Juhi
AU - Falade-Nwulia, Oluwaseun
AU - Sulkowski, Mark S.
AU - Thomas, David L.
AU - Melia, Michael T.
N1 - Funding Information:
This work was supported by the Centers for Disease Control and Prevention through cooperative agreement CDC-RFA-PS14-1413, Community-based Programs to Test and Cure Hepatitis C. The primary author also received support from the National Institute on Drug Abuse [R37DA013806] and the National Institute of Allergy and Infectious Diseases (Johns Hopkins University Center for AIDS Research [P30AI094189]).
Funding Information:
This work was supported by the Centers for Disease Control and Prevention through cooperative agreement CDC‐RFA‐PS14‐1413, Community‐based Programs to Test and Cure Hepatitis C. The primary author also received support from the National Institute on Drug Abuse [R37DA013806] and the National Institute of Allergy and Infectious Diseases (Johns Hopkins University Center for AIDS Research [P30AI094189]).
Publisher Copyright:
© 2020 John Wiley & Sons Ltd
PY - 2020/12/1
Y1 - 2020/12/1
N2 - In 2014, trained healthcare provider capacity was insufficient to deliver care to an estimated 70 000 persons in Maryland with chronic hepatitis C virus (HCV) infection. The goal of Maryland Community Based Programs to Test and Cure Hepatitis C, a public health implementation project, was to improve HCV treatment access by expanding the workforce. Sharing the Cure (STC) was a package of services deployed 10/1/14-9/30/18 that included enhanced information technology and public health infrastructure, primary care provider training and practice transformation. Nine primary care sites enrolled. HCV clinical outcomes were documented among individuals who presented for care at sites and met criteria for HCV testing including risk factor or birth cohort (born between 1945 and 1965) based testing. Fifty-three providers completed the STC training. STC providers identified 3237 HCV antibody-positive patients of which 2624 (81%) were RNA+. Of those HCV RNA+, 1739 (66%) were staged, 932 (36%) were prescribed treatment, 838 (32%) started treatment, 721 (27%) completed treatment and 543 (21%) achieved cure. Among 1739 patients staged, 693 (40%) patients had a liver fibrosis assessment score < F2, rendering them ineligible for treatment under Maryland Medicaid guidelines. HCV RNA testing among HCV antibody-positive people increased from 40% (baseline) to 95% among STC providers. Of 554 patients with virologic data reported, 543 (98%) achieved cure. Primary care practices can effectively serve as HCV treatment centers to expand treatment access. However, criteria by insurance providers in Maryland were a major barrier to treatment.
AB - In 2014, trained healthcare provider capacity was insufficient to deliver care to an estimated 70 000 persons in Maryland with chronic hepatitis C virus (HCV) infection. The goal of Maryland Community Based Programs to Test and Cure Hepatitis C, a public health implementation project, was to improve HCV treatment access by expanding the workforce. Sharing the Cure (STC) was a package of services deployed 10/1/14-9/30/18 that included enhanced information technology and public health infrastructure, primary care provider training and practice transformation. Nine primary care sites enrolled. HCV clinical outcomes were documented among individuals who presented for care at sites and met criteria for HCV testing including risk factor or birth cohort (born between 1945 and 1965) based testing. Fifty-three providers completed the STC training. STC providers identified 3237 HCV antibody-positive patients of which 2624 (81%) were RNA+. Of those HCV RNA+, 1739 (66%) were staged, 932 (36%) were prescribed treatment, 838 (32%) started treatment, 721 (27%) completed treatment and 543 (21%) achieved cure. Among 1739 patients staged, 693 (40%) patients had a liver fibrosis assessment score < F2, rendering them ineligible for treatment under Maryland Medicaid guidelines. HCV RNA testing among HCV antibody-positive people increased from 40% (baseline) to 95% among STC providers. Of 554 patients with virologic data reported, 543 (98%) achieved cure. Primary care practices can effectively serve as HCV treatment centers to expand treatment access. However, criteria by insurance providers in Maryland were a major barrier to treatment.
KW - hepatitis c
KW - hepatitis c care continuum
KW - provider task shifting
KW - public health
KW - video conference training
UR - http://www.scopus.com/inward/record.url?scp=85088955080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088955080&partnerID=8YFLogxK
U2 - 10.1111/jvh.13360
DO - 10.1111/jvh.13360
M3 - Article
C2 - 32671942
AN - SCOPUS:85088955080
SN - 1352-0504
VL - 27
SP - 1388
EP - 1395
JO - Journal of viral hepatitis
JF - Journal of viral hepatitis
IS - 12
ER -